ArticleFrontiers in pharmacology2025

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective.

Dandan Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.